[Skip to Navigation]
Sign In
From the JAMA Network
October 2018

Redefining the Value Proposition of Precision Oncology: Can We Integrate Genomic Testing Without Overselling It?

Author Affiliations
  • 1Thoracic Oncology Program, Swedish Cancer Institute, Seattle, Washington
JAMA Oncol. 2018;4(10):1423-1424. doi:10.1001/jamaoncol.2018.3729

We are currently experiencing growing pains as we struggle to integrate broad-based genomic sequencing (BGS) into the delivery of routine cancer care, a process that should accelerate in the wake of the recent liberal US Food and Drug Administration (FDA) approval of BGS for advanced cancers.1 Among the many challenges is our need to calibrate the expectations of our patients and ourselves about the probability that BGS will identify a personalized, highly targeted, and effective therapy for their specific cancer. Presently, this is hindered by the gulf between the scant evidence and the hyperbolic edicts from leading individuals, institutions, and media outlets extolling the benefits of precision medicine.

Add or change institution